TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11883765

Group type: EXPERIMENTAL
Intervention: ACE strategy
Number of subjects: 62

Group type: COMPARATOR
Intervention: SPEAK strategy
Number of subjects: 62

Group type: COMPARATOR
Intervention: CIS strategy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: HINT sentences in quiet
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CUNY sentences at +10 dB signal to noise ratio
Number of subjects: 62
Study: 10201415

Group type: EXPERIMENTAL
Intervention: Free fall startle response in young normal subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free fall startle response in elderly subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voluntary tibialis EMG activation in response to startling stimulus (fall)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free fall startle response in patients with absent vestibular function
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free fall startle response in patients with idiopathic Parkinson's disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free fall startle response in patients with multiple system atrophy (MSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free fall startle response in patients with Steele-Richardson-Olszewski (SRO) syndrome
Number of subjects: 0
Study: 7767515

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (300 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2152662

Group type: EXPERIMENTAL
Intervention: Enalapril, 5 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 36
Study: 7439251

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg initially, increased to 240 or 320 mg if necessary)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg initially, increased to 300 or 400 mg if necessary)
Number of subjects: 34
Study: 31810781

Group type: EXPERIMENTAL
Intervention: Self-reported vaccine coverage for seasonal influenza vaccine (recommended, 2016/17 season)
Number of subjects: 1539

Group type: EXPERIMENTAL
Intervention: Self-reported vaccine coverage for Bacillus Calmette-Guérin vaccine (mandatory)
Number of subjects: 1539

Group type: EXPERIMENTAL
Intervention: Vaccine hesitancy prevalence rate
Number of subjects: 1539

Group type: EXPERIMENTAL
Intervention: Vaccine hesitancy concerning seasonal influenza or A(H1N1) vaccines
Number of subjects: 1539

Group type: EXPERIMENTAL
Intervention: Vaccine hesitancy concerning hepatitis B vaccine
Number of subjects: 1539

Group type: EXPERIMENTAL
Intervention: Association of VH with trust in health authorities
Number of subjects: 1539
Study: 31124581

Group type: EXPERIMENTAL
Intervention: Medac Escherichia coli asparaginase
Number of subjects: 599

Group type: COMPARATOR
Intervention: Erwinia asparaginase
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Dexamethasone (6 mg/m2/day)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Prednisolone (60 mg/m2/day)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Intensified CNS-directed therapy
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Intensified induction chemotherapy
Number of subjects: 599
Study: 27647659

Group type: EXPERIMENTAL
Intervention: DASM training with three repetitions of the anaesthesia technique (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with only theoretical lecture and clinical demonstration (Group 2)
Number of subjects: 20
Study: 25464226

Group type: EXPERIMENTAL
Intervention: Patients with metabolic syndrome (METS)
Number of subjects: 6648

Group type: EXPERIMENTAL
Intervention: Patients with METS and no type 2 diabetes mellitus (DM)
Number of subjects: 6648

Group type: EXPERIMENTAL
Intervention: Patients with diabetes mellitus (DM) and no metabolic syndrome (METS)
Number of subjects: 6648

Group type: EXPERIMENTAL
Intervention: Patients with METS and DM
Number of subjects: 6648
Study: 23745533

Group type: EXPERIMENTAL
Intervention: Thermosensitive poloxamer (TPX)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Merogel
Number of subjects: 66
Study: 22289558

Group type: EXPERIMENTAL
Intervention: LMA-D (laryngeal mask airway and deep removal)
Number of subjects: 168

Group type: COMPARATOR
Intervention: ET-A (endotracheal tube and extubation whilst awake)
Number of subjects: 168

Group type: COMPARATOR
Intervention: ET-D (endotracheal tube and deep extubation)
Number of subjects: 168
Study: 19054264

Group type: COMPARATOR
Intervention: Covered Niti-S stent
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Double-layered Niti-S stent
Number of subjects: 37
Study: 16584098

Group type: EXPERIMENTAL
Intervention: Drug treatments
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Stepped care model
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Meta-analyses of RCTs
Number of subjects: 8000
Study: 15090972

Group type: EXPERIMENTAL
Intervention: Intravenous GLP-1 (1.2 pmol x kg x min) for 8 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion for 8 hours
Number of subjects: 8
Study: 11296544

Group type: EXPERIMENTAL
Intervention: NIM 200 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: NIM 400 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: NIM 100 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 9342788

Group type: EXPERIMENTAL
Intervention: THA 25 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: THA 50 mg
Number of subjects: 19
Study: 8509691

Group type: EXPERIMENTAL
Intervention: Betnesol‐N ear drops
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control (no ear drops)
Number of subjects: 162
Study: 2956876

Group type: EXPERIMENTAL
Intervention: Enoximone (50 to 100 mg 3 times daily)
Number of subjects: 30
Study: 29915986

Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate loading (CHO)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 27208905

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (600 mg fixed dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous trastuzumab (8 mg/kg loading, 6 mg/kg maintenance)
Number of subjects: 0
Study: 24864325

Group type: EXPERIMENTAL
Intervention: Femtosecond laser CCI
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual CCI
Number of subjects: 60
Study: 22413441

Group type: EXPERIMENTAL
Intervention: Semi-lateral position (group SL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supine position with uterine displacement (group UD)
Number of subjects: 0
Study: 20857869

Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 18473286

Group type: EXPERIMENTAL
Intervention: Benfotiamine 600 mg per day
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Benfotiamine 300 mg per day
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 15958063

Group type: EXPERIMENTAL
Intervention: Autologous haematopoietic stem cell transplant (HSCT)
Number of subjects: 700
Study: 12410858

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study: 10329293

Group type: EXPERIMENTAL
Intervention: Principal component analysis (PCA) with varying numbers of principal components retained
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analytic and test set estimates of generalization
Number of subjects: 0
Study: 8519722

Group type: COMPARATOR
Intervention: Fentanyl (10 micrograms/mL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl/bupivacaine (0.1%) mixture
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 1708716

Group type: COMPARATOR
Intervention: No-information condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial information conditions (direction, hand, extent precued)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial information conditions (all precue conditions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial information conditions (M3 component)
Number of subjects: 0
Study: 7143286

Group type: EXPERIMENTAL
Intervention: Biofeedback training for cardiac acceleration (2-5 sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Biofeedback assisted training in cardiac constancy (1 session)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Biofeedback training for cardiac acceleration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Biofeedback assisted training in cardiac constancy
Number of subjects: 24
Study: 6368958

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2 vitamin D3 (approximately 0.25 microgram/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 30124721

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo→Guselkumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab→Guselkumab
Number of subjects: 0
Study: 27128357

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) plus Treatment as Usual (TAU)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) plus Treatment as Usual (TAU)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 106
Study: 24785463

Group type: EXPERIMENTAL
Intervention: Suboccipital soft tissue inhibition
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Occiput-atlas-axis manipulation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combined treatment of both techniques
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 22582764

Group type: EXPERIMENTAL
Intervention: JASP/ER intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 20079617

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18540738

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Training (ACT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Educational Control Workshop
Number of subjects: 59
Study: 15863798

Group type: EXPERIMENTAL
Intervention: Sibutramine (up to 15 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 37
Study: 12195728

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg orally for 3 months)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Metoclopramide (5 mg intravenously)
Number of subjects: 7
Study: 7727324

Group type: EXPERIMENTAL
Intervention: Loading dose 1 mg morphine epidurally and continuous infusion of bupivacaine 0.75% + 0.2 mg/mL morphine at an infusion rate of 0.8 mL/hr
Number of subjects: 60

Group type: COMPARATOR
Intervention: Loading dose 0.5 mg morphine epidurally and continuous infusion of bupivacaine 0.75% + 0.1 mg/mL morphine at an infusion rate of 0.8 mL/hr
Number of subjects: 60
Study: 2109522

Group type: EXPERIMENTAL
Intervention: Tenoretic (100 mg atenolol + 25 mg chlorthalidone)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atenolol alone (100 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chlorthalidone alone (25 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atenolol (100 mg) plus Chlorthalidone (25 mg) taken separately
Number of subjects: 24
Study: 6975811

Group type: EXPERIMENTAL
Intervention: Oral chloramphenicol (75 mg/kg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous chloramphenicol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral chloramphenicol
Number of subjects: 44
Study: 30990777

Group type: EXPERIMENTAL
Intervention: Porcine-based wound matrix dressing plus negative pressure wound therapy (NPWT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Negative pressure wound therapy (NPWT) alone
Number of subjects: 16
Study: 30094849

Group type: EXPERIMENTAL
Intervention: Warm water (42°C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold water (23°C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer cure time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warm water and longer cure times
Number of subjects: 0
Study: 26709567

Group type: EXPERIMENTAL
Intervention: Single-portal technique
Number of subjects: 156

Group type: COMPARATOR
Intervention: 2-portal technique
Number of subjects: 156
Study: 24269494

Group type: EXPERIMENTAL
Intervention: Fear of social threat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fear of physical pain
Number of subjects: 0
Study: 21410537

Group type: EXPERIMENTAL
Intervention: Custom-molded rigid heel cup
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sports shoe without heel cup
Number of subjects: 50
Study: 21110140

Group type: EXPERIMENTAL
Intervention: Bassini group
Number of subjects: 552

Group type: COMPARATOR
Intervention: Tension-free mesh group
Number of subjects: 552
Study: 17415690

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% (Trav/Tim)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Latanoprost 0.005%/timolol 0.5% (Lat/Tim)
Number of subjects: 408
Study: 15704096

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham LLLT
Number of subjects: 88
Study: 11324406

Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nonfluoridated dentifrice
Number of subjects: 58
Study: 9390584

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 41
Study: 8189280

Group type: EXPERIMENTAL
Intervention: Proparacaine (2 drops)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Saline placebo (2 drops)
Number of subjects: 47
Study: 3074608

Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30595342

Group type: EXPERIMENTAL
Intervention: Female patient with psychological symptoms
Number of subjects: 225

Group type: COMPARATOR
Intervention: Male patient with psychological symptoms
Number of subjects: 225
Study: 28593473

Group type: EXPERIMENTAL
Intervention: Erenumab (AMG 334); subcutaneous administration; pharmacokinetics characterized by a two-compartment target-mediated drug disposition model; absorption half-life of 1.6 days; bioavailability of 74%.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erenumab (AMG 334); effects evaluated in relation to body weight, gender, and age.
Number of subjects: 0
Study: 25069999

Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy with polidocanol 0.5%
Number of subjects: 56

Group type: COMPARATOR
Intervention: Long‐pulsed neodymium‐doped yttrium aluminium garnet (Nd:YAG) laser
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both therapies (sclerotherapy and Nd:YAG laser)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Pain perception
Number of subjects: 56
Study: 23591157

Group type: EXPERIMENTAL
Intervention: FBV supplementation for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Moderate exercise (single bout)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FBV supplementation and controlled walking
Number of subjects: 42
Study: 21891918

Group type: EXPERIMENTAL
Intervention: Mtwo rotary system
Number of subjects: 140

Group type: COMPARATOR
Intervention: K-file
Number of subjects: 140
Study: 19444535

Group type: EXPERIMENTAL
Intervention: Uric acid (UA) treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 24
Study: 16772858

Group type: EXPERIMENTAL
Intervention: Suggestions for anomalous experiences
Number of subjects: 0

Group type: COMPARATOR
Intervention: No suggestions for anomalous experiences (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suggestion condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual apparitions
Number of subjects: 0
Study: 15284771

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (100 mg every 4 hours up to 6 doses)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Intravenous oxytocin (administered by standardized protocol)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 198

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 198
Study: 11376176

Group type: EXPERIMENTAL
Intervention: Surgical hematoma evacuation within 4 hours of symptom onset
Number of subjects: 11

Group type: COMPARATOR
Intervention: Surgical treatment within 12 hours of symptom onset
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Smaller postsurgical hematoma volume
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Postoperative rebleeding
Number of subjects: 11
Study: 9382054

Group type: EXPERIMENTAL
Intervention: Combination therapy (mesalamine enema and mesalamine tablets)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mesalamine rectal enema
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral mesalamine tablets
Number of subjects: 60
Study: 8257143

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) fluconazole, 100 mg, administered by constant-rate infusion over 30 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral (p.o.) fluconazole, 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous (i.v.) fluconazole, 100 mg
Number of subjects: 10
Study: 4085410

Group type: EXPERIMENTAL
Intervention: 300 mg tiapride
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1 g aspirin
Number of subjects: 20
Study: 30082217

Group type: EXPERIMENTAL
Intervention: Intranasal arginine vasopressin (AVP)
Number of subjects: 653
Study: 30243662

Group type: EXPERIMENTAL
Intervention: XP Shaper (XP) operated at 3000 rpm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyflex EDM 'one file' (EDM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: WaveOne Gold Primary (WOG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: XP Shaper (XP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study: 26424292

Group type: EXPERIMENTAL
Intervention: Moluodan
Number of subjects: 196

Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 196
Study: 24176199

Group type: EXPERIMENTAL
Intervention: Active Treatment (AT, n=149)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC, n=130)
Number of subjects: 279
Study: 22739219

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 0
Study: 20228458

Group type: EXPERIMENTAL
Intervention: Oral lycopene 8 mg daily with radiotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo with radiotherapy
Number of subjects: 50
Study: 18572037

Group type: EXPERIMENTAL
Intervention: Fenofibrate (FEN)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet (CRD)
Number of subjects: 37
Study: 15948817

Group type: EXPERIMENTAL
Intervention: NP-LS regimen (prepackaged low-residue diet with LoSo Prep containing magnesium citrate, bisocodyl tablets, and bisocodyl suppository)
Number of subjects: 506

Group type: COMPARATOR
Intervention: 2F regimen (clear liquid diet with double-dose sodium phosphate)
Number of subjects: 506
Study: 12806559

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro fertilization (IVF)
Number of subjects: 0
Study: 10491521

Group type: EXPERIMENTAL
Intervention: VBMCP + rIFN(alpha2)
Number of subjects: 628

Group type: COMPARATOR
Intervention: VBMCP
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: VBMCP + HiCy
Number of subjects: 628
Study: 9177625

Group type: EXPERIMENTAL
Intervention: 150 mg prolonged-release diclofenac sodium
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3 enteric-coated tablets/day of 50 mg diclofenac sodium
Number of subjects: 20
Study: 8191328

Group type: EXPERIMENTAL
Intervention: 1.5 mg prostaglandin E2 (PGE2) gel extra‐amniotically
Number of subjects: 20

Group type: COMPARATOR
Intervention: 25 mg prostaglandin F2 alpha (PGF2 alpha) intra‐amniotically
Number of subjects: 20
Study: 3546147

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg t.i.d. orally for ten days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Amoxicillin 1 g t.i.d. orally for ten days
Number of subjects: 32
Study: 31714396

Group type: EXPERIMENTAL
Intervention: Maximal-intensity aerobic interval training (MAIT) at 95-100% of heart rate reserve, 3 d/wk for 4 wk
Number of subjects: 47

Group type: COMPARATOR
Intervention: High-intensity aerobic interval training (HAIT) at 85% of heart rate reserve, 3 d/wk for 4 wk
Number of subjects: 47
Study: 28780493

Group type: EXPERIMENTAL
Intervention: Pain Assessment in Advanced Dementia (PAINAD) tool
Number of subjects: 602

Group type: COMPARATOR
Intervention: Standard methods for pain assessment
Number of subjects: 602
Study: 26940081

Group type: EXPERIMENTAL
Intervention: Carbetocin 100 μg
Number of subjects: 114

Group type: COMPARATOR
Intervention: Oxytocin 5 international units
Number of subjects: 114
Study: 23065358

Group type: EXPERIMENTAL
Intervention: CD34+ stem cell transplantation
Number of subjects: 110

Group type: COMPARATOR
Intervention: No cell therapy (controls)
Number of subjects: 110
Study: 21392602

Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs) administered transendocardially
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Whole bone marrow mononuclear cells (BMCs) administered transendocardially
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (for both MSC and BMC groups)
Number of subjects: 60
Study: 20082783

Group type: EXPERIMENTAL
Intervention: Bone morphogenetic proteins (BMPs)
Number of subjects: 0
Study: 17336720

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 3029
Study: 15156256

Group type: EXPERIMENTAL
Intervention: Sulodexide treatment for 24 months after 6 months of oral anticoagulants.
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control group (no sulodexide treatment).
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Sulodexide treatment for 24 months.
Number of subjects: 405
Study: 11384827

Group type: EXPERIMENTAL
Intervention: Leaflet containing detailed information about potential side effects
Number of subjects: 41

Group type: COMPARATOR
Intervention: Leaflet without detailed risk information
Number of subjects: 41